Comparative Pharmacology
Head-to-head clinical analysis: ARYNTA versus DURAGESIC 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARYNTA versus DURAGESIC 25.
ARYNTA vs DURAGESIC-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARYNTA (pembrolizumab) is a humanized monoclonal antibody that binds to the programmed death-1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2, thereby restoring anti-tumor immune responses.
Fentanyl is a mu-opioid receptor agonist that produces analgesia and sedation by mimicking endogenous opioids in the central nervous system.
400 mg orally once daily
Apply 25 mcg/hour transdermally every 72 hours; initial dose in opioid-naive patients: 25 mcg/hour is not recommended; use lower strength or immediate-release opioid first.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours in healthy adults, prolonged to 6-12 hours in moderate to severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life 22-25 hours (range 13-31 h) after 72-h transdermal application; prolonged in elderly, hepatic or renal impairment
Primarily renal elimination (70-80% unchanged), with 10-15% fecal excretion via biliary secretion.
Renal (75% as metabolites, <10% unchanged); fecal (9%)
Category C
Category C
Opioid Analgesic
Opioid Analgesic